<SEC-DOCUMENT>0001104659-22-075759.txt : 20220729
<SEC-HEADER>0001104659-22-075759.hdr.sgml : 20220729
<ACCEPTANCE-DATETIME>20220629152116
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-22-075759
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<IMG SRC="tm2220033d1_correspimage001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">June 29, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S.&nbsp;Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporate Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mail Stop 4720</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. &nbsp;20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%; text-align: center">Re:</TD><TD STYLE="text-align: justify; width: 90%"><U>Protalix BioTherapeutics, Inc.</U></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%; text-align: left"></TD><TD STYLE="text-align: justify; width: 90%"><U>Form 10-K for the Fiscal Year Ended December 31, 2021</U></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%; text-align: left"></TD><TD STYLE="text-align: justify; width: 90%"><U>Filed March 31, 2022</U></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%; text-align: left"></TD><TD STYLE="text-align: justify; width: 90%"><U>File No. 001-33357</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Transmitted herewith is the response of Protalix
BioTherapeutics, Inc. (the &#8220;Company&#8221;) to the Staff&#8217;s comment to the Company&#8217;s Annual Report on Form 10-K for the
fiscal year ended December&nbsp;31, 2021 (the &#8220;Form 10-K&#8221;), which comment was set forth in the Staff&#8217;s letter dated
June&nbsp;23, 2022 (the &#8220;Comment Letter&#8221;) to Eyal Rubin, the Company&#8217;s Chief Financial Officer. For ease of reference,
the Company has noted the Staff&#8217;s comment in bold-faced type and the response in regular type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Management's Discussion and Analysis of Financial
Condition and Results of Operations<BR></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><B>You disclose on page 64 that you currently
do not record and maintain research and development costs per project. You also disclose on page 66 that the decrease in your research
and development expense was primarily due to the completion of the three phase III clinical trials of PRX-102. Please revise your future
filings to provide a quantified breakdown of research and development costs by nature of expense for each period presented. As part of
your breakdown, separately identify the amount of cost reimbursement netted against such expenses. Please provide us with an example of
your proposed disclosure in your response.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><U>Response</U>: The Company
respectfully acknowledges the Staff&#8217;s comment and provides an example of the requested breakdown of research and development
expenses below. The Company will provide, in its future filings with the U.S. Securities and Exchange Commission, where applicable,
a quantified breakdown of research and development costs by nature of expense for each period presented consistent with the
narrative disclosure example following this paragraph. The Company notes, however, that the example does not identify any cost
reimbursement that are netted against the research and development expenses as the Company has determined that for the current
period, the amount of such reimbursements do not reach a level of materiality that warrants such disclosure. The Company further
notes that the foregoing example sets forth the requested disclosure had it been included in the Form&nbsp;10&#45;K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: left"><B>Research and Development Expenses,
Net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: left">For the year ended December&nbsp;31,
2021, our total research and development expenses were approximately $29.7 million comprised of approximately $18.3 million in subcontractor-related
expenses, approximately $7.4 million of salary and related expenses, approximately $1.2 million of materials-related expenses and approximately
$2.8&nbsp;million of other expenses. For the year ended December&nbsp;31, 2020, our total research and development expenses were approximately
$38.2&nbsp;million comprised of approximately $21.9 million of subcontractor-related expenses, approximately $10.7 million of salary and
related expenses, approximately $1.7&nbsp;million of materials-related expenses and approximately $4.0 million of other expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: left">The decrease in research and developments
expenses of $8.5 million, or 22%, from the year ended December&nbsp;31, 2020 compared to the year ended December&nbsp;31, 2021 was primarily
due to the completion of our three phase III clinical trials of PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: justify">We expect research and development
expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of
our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We thank you in advance for your time and attention to this response
letter. Should you wish to discuss this response letter at any time, please do not hesitate to contact me at +972 (4) 902-8100 or Eyal.Rubin@protalix.com
or the Company&#8217;s counsel, Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176 or <U>bhirshberg@mayerbrown.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Eyal Rubin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyal
    Rubin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr.
    Vice President and Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix
    BioTherapeutics, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dror
    Bashan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix
    BioTherapeutics, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anna
    Pinedo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Hirshberg</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mayer
    Brown LLP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2220033d1_correspimage001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2220033d1_correspimage001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X *8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^D_QY_P %
M)_VG;G]J'X__ +-?[./["1_:"NOV?+SP?8^+?$]K\>?#OP_:(^*_#H\3:!_Q
M(O$WA-V#D,48QSF,XPC%0IK)UW_@JY\;/@#<:;K/[;?_  3W^,7[/OPJU*\%
MC??%SPOX\\-?&SPAX8\P.(SXF'A.(2Q+(5<!UX(5\(Q4BC]AG_E+1_P5J^G[
M-'_JOQ7VA_P4/^+OP5^%/[(/QYU7XZZOHEKX5\1_"KQOX:M?#.K7L::IXOUK
M7/#MY'H?AW1-#G<2W6OSW!1;>*WB>2.=4G<K&&,8!R'[<O[>EI^R9^SQ\-/V
M@? 7@K2OCUI7Q2^(WP[\!^%-/L/%Y\'Z7J^G?$/0?$6OZ%XBT7Q!#X8\:1RQ
MM#HD3I'+9.C"1)"T1"(_@$_[=_\ P4KTF--1UK_@D5XTN],@&+G_ (1?]IKP
M!JVLL .?*T#_ (1(2.2#NR&8CC! Q7Y@?';P?X[\$?\ !#W_ ()P>&_B-:7E
MIXJLOVD_@!J+V=Z!_:FGZ-XD\1_$_P 1>&@S#)9X_"NN^'QC^%3AOX0/ZW*
M/@C]B_\ ;W^$W[9<'C31]!T7Q;\,?C#\+[YM.^*_P3^)^G+HWQ!\#SR21B-Y
MX"^V;0I92!%=(@5V)C>*/"&63]L_]O3X0?L6:+X7A\66WB#Q_P#%7XD7\FE_
M"?X)?#FS36OB/\1M8S*A^S:!@R0>'898XTNO%4L9@C.4CWO')O\ @K6+WPYJ
M_P#P7V\!W/P>"76J^'/V0O&&G_M37^@LK:8AEN@?AWHGB3YMH\1(7^'4CKGY
M+1?"*A05""#_ ()I>'(OVI_VP/VV?^"@OQ&C77=;\-_&?7?V7OV>A?K\WPY^
M&WPW4?\ "0'PY(''EIXT3Q#H+/LC9]Q\62[DB\9S1R@'=V'QJ_X+<?$.R3Q?
MX8_9/_9 ^#OAF[87.G?#WXQ_$[QWJ_Q*DTI 1Y7B.3PL?^$2\-S;4;=&"9/E
M.5-=%\(?^"GWBSPK\7?#7[-7_!0+X ZM^R9\8O'-^^E?#;QBOB)/%?P)^*VJ
MK$R20^&?'T<8CT"3<-JP7KE5D9B)8@-K?LE7Q)^WM^ROX)_:]_9B^*'PF\7:
M;;7&I'P]K/B/P)KA3.J>#OB1H6AROX9U[P\2H:.>&3=D!MA25MZ,S(T !RW[
M4G[07[8GPF\<>&M%_9X_8AO_ -ICPMJOAIK_ %SQM8_&?P+\.3X>UI=6$0T
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M'A+PKXFAF$7C3X?6WC&>UG\;)XB\9);S>9;QPR 'JG@']OW0-;^.7P\_9?\
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MAB14CM_$3Q)<R[@\4*NHV%% 'TQ!;):PQ0V]O'!;6P"V]K!#'$$4 @*FV<1
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L+.Q@LD6TMK18HX+2"RM0T%NEO!8QPP01F)(GC@BBCB@1C$J*$"@HHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
